Schizophrenia is a serious psychiatric illness with a life-time risk of approximately one percent. Many of the patients, but not all, benefit from treatment with anti-psychotic drugs known to block dopamine D2-like receptors. The use of conventional neuroleptics is, however, hampered by the risk of extrapyramidal side-effects. Tardive dyskinesia (TD) is usually regarded as the most serious of these drug-induced movement disorders due to its high prevalence and potentially irreversible nature. In this study, we have investigated the genetic variation of the dopamine D3 receptor gene (DRD3) as a putative risk factor for TD in schizophrenic patients receiving long-term anti-psychotic drug therapy. We found a high frequency (22-24%) of homozygosity for the Ser9Gly variant (allele 2) of the DRD3 gene among subjects with TD in both a cross-sectional and a longitudinal evaluation, as compared with the relative underrepresentation (4-6%) of this genotype in patients with no or fluctuating TD. This result indicates that autosomal inheritance of two polymorphic Ser9Gly alleles (2-2 genotype), but not homozygosity for the wild-type allele (1-1 genotype), is a susceptibility factor for the development of TD, an observation which may improve the understanding of the pathophysiological mechanisms of TD and influence the design and choice of future anti-psychotic drugs. The correlation between a serious motor side-effect and a genetic marker could lead to selection bias in the sampling of schizophrenic patients for genetic studies, and may therefore explain the apparent association reported between susceptibility for schizophrenia per se and homozygosity for the DRD3 gene.
Introduction
involvement of the different dopamine receptor genes, with special focus on the dopamine D2-like (D2, D3 The pathogenesis of schizophrenia and the mechand D4) receptor subtypes. The reported association anisms involved in the clinical action and side-effects between susceptibility for schizophrenia and genetic of neuroleptic treatment have not been elucidated. For variation of the dopamine D3-receptor is intriguing, [5] [6] [7] [8] [9] [10] [11] several decades, family, twin and adoption studies although several studies have failed to confirm this have strongly pointed to inherited predisposing factors apparent association. [12] [13] [14] [15] [16] [17] [18] [19] [20] in the etiology of schizophrenia, but so far, both genetic The beneficial effect of neuroleptics in the treatment linkage and association analyses have yielded conflictof schizophrenia is fully established. The efficacy of ing results. 1 The initial study in 1988 reporting linkage these drugs is tightly correlated to their affinity for between schizophrenia and markers on chromosome 5 and blockage of dopamine D2-like receptors in the was not confirmed by others, 2 and the role of the chrobrain. [21] [22] The use of conventional anti-psychotics is, mosome 6 locus recently published by several groups however, hampered by the risk of extrapyramidal sideremains to be established with respect to the etiology of effects, such as tardive dyskinesia (TD), parkinsonism schizophrenia. [3] [4] In a similar way, the candidate gene and akathisia. TD is usually regarded as the most seriapproach has produced conflicting data. The dopamine ous of these neuroleptic-induced movement disorders hypothesis of schizophrenia has attracted much attendue to its high prevalence and potentially irreversible tion and several studies have investigated the possible nature. Aging is the most prominent risk factor, but schizophrenia-related pathophysiological factors, organic brain damage, high neuroleptic dose, female 51 and diagnosed according to the Schooler & Kane criteria if there were at least 'moderThe role of the dopamine D3-receptor (DRD3) in TD should be interesting to investigate, since most neuroate' abnormal involuntary movements in one or more of the seven body areas examined, or at least 'mild' leptics are potent inhibitors of dopamine binding to DRD3. The human DRD3 gene has been characterized movements in two or more areas. 52 To assess inter-rater agreement, 19 patients were examined by both psyand localized to chromosome 3q13.3. 10, [37] [38] It contains a polymorphic base in codon nine, giving rise to a prechiatrists. When the diagnostic criteria were applied there was agreement as to whether TD was present or dicted serine to glycine substitution in the N-terminal extracellular part of the receptor. 39 The DNA alteration absent in 15 of the 19 subjects rated. Seventy-five of the 100 patients had been examined results in the creation of a BalI (MscI) restriction enzyme site, which can be used to detect the polymoron at least two of the five previous assessments of TD in the Nithsdale cohort of schizophrenic patients, phism. In Caucasian and Asian populations, the frequency of the polymorphic Ser9Gly allele has been which took place in 1981, 1982, 1984, 1989 and 1993. 26,47,53-55 These subjects were included in the reported to vary between 24 and 42%. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Recently, expression studies have demonstrated that the wildlongitudinal evaluation of TD, defined in the following way: (i) TD-never: at least three assessments, but type and polymorphic D3 receptors may differ with respect to the binding affinity for dopamine. 40 In [41] [42] [43] [44] [45] In the present study we investigated the genetic variation of the DRD3 gene as a putative ments, with Schooler & Kane criteria fulfilled on all occasions. The patients in the TD-never and TD-flucrisk factor for TD, using a sample from the Nithsdale cohort of schizophrenic patients receiving long-term tuating groups, and the TD-developed and TD-persistent groups were pooled together prior to the correlation antipsychotic drug therapy. 36, 46 We found that homozygosity for the Ser9Gly variant of the DRD3 gene with the genetic data. Twenty-five patients were assessed less than three times. apparently is a susceptibility factor for both the crosssectional prevalence and longitudinal persistence of TD in schizophrenic patients.
Genotyping To identify the wild-type and polymorphic variant of the DRD3 gene, 10 ml of EDTA-anticoagulated venous Subjects and methods blood was drawn from each patient after the clinical Patients were recruited from the cohort of Nithsdale examination. Genomic DNA was extracted from the schizophrenic patients in South-west Scotland. Since leukocytes by Qiagen Blood and Cell Culture DNA kit 1981, regular censuses have been carried out to ident-(Qiagen-tip 100; Qiagen, Hilden, Germany) according ify all known schizophrenic patients living in the to the manufacturer's recommendations. The genotypNithsdale area. 46 In the present study, patients identing was performed blind to the clinical status of the ified in the most recent census (1993, n = 170) were patients. invited to participate. 47 The project was carried out The 5′-end of the human DRD3 gene containing the with the approval of the local ethical committee, and codon 9 polymorphism was amplified by polymerase informed consent was obtained from all participants.
chain reaction (PCR), with minor modifications as compared to the method previously described by others. 39 
Patient characteristics
One hundred patients agreed to participate and were A 50-l PCR reaction was carried out with the forward primer drd3-1 5′-TGGGCTATGGCATCTCTGAG-3′ and examined between November 1994 and July 1995. Forty-four patients (44%) were female, mean age 57 the reverse primer drd3-2 5′CCACCAGCAAGTCTGCC ACA-3′ in the presence of 10 mM Tris-HCl (pH 9.0 at years (s.d. 16), mean length of illness 25 years (s.d. 15); 56 patients (56%) were male, mean age 50 years (s.d. 25°C), 1.5 mM MgCl 2 , 50 mM KCl, 0.01% (w/v) gelatin, 0.1% Triton X-100, 0.5 M of each primer, 0.125 mM 14), mean length of illness 21 years (s.d. 14). All patients had a firm clinical diagnosis of schizophrenia of each dNTP, 0.2 U of SuperTaq DNA polymerase (HT Biotechnology, Cambridge, UK) and 400 ng of genomic (ICD-9, 295), 48 of whom 76 subjects (76%) fulfilled the DSM-III-R criteria for schizophrenia when the Oper-DNA. Amplification was performed on a Perkin-Elmer 2400 Thermal Cycler (Perkin-Elmer, Foster City, CA, ational Criteria Checklist for Psychotic Illness (OCCPI) was applied to the patients' case records and the com-USA) under the following conditions: an initial denaturation at 96°C for 1 min, followed by 33 cycles of 96°C puter programme OPCRIT used to analyse the data.
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for 20 s, 62°C for 15 s and 72°C for 1 min, with a final 1.05-3.93)) (Table 1) . This difference was due to a large over-representation of the 2-2 genotype in the TD group elongation step at 72°C for 7 min. The resulting 241-bp PCR product was digested with the restriction enzyme and a reciprocal low frequency of 2-2 homozygotes among the patients without TD (22% vs 4%; P = 0.018, MscI (New England Biolabs, Beverly, MA, USA) as recommended by the manufacturer. The digests were run odds ratio 6.5 (95% CI 1.3-62.4)). TD was present in 11 out of 13 subjects (85%) with the 2-2 genotype, in and analyzed by electrophoresis on a 3% NuSieve agarose gel.
17 out of 36 heterozygotes (47%) and in 23 out of 51 patients (45%) with the 1-1 genotype.
Statistical analysis
The difference between groups of patients with respect DRD3 gene polymorphism and longitudinal TD Seventy-five (75%) of the patients in the present study to allele frequencies and genotypes was compared using a conservative two-tailed Fisher exact test (twohad been examined for TD on at least three different occasions since 1981, which enabled us to evaluate the times one-sided). To test whether the distribution of genotypes was in accordance with a Hardy-Weinberg relationship between longitudinal TD and the DRD3 gene variants. As shown in Table 2 , twenty-five (33%) equilibrium, we used the chi-square test. Mann-Whitney U test was used to compare the difference in age of these patients had fulfilled the Schooler & Kane criteria for TD on all or at least the two last assessments between the groups. Probability values of 0.05 or less were regarded as statistically significant.
(TD-developed and TD-persistent) and they were significantly older than the subjects who had never or only occasionally fulfilled the TD criteria (TD-fluctuResults ating and TD-never) ( The allele frequency of the two different variants of the As demonstrated in the cross-sectional evaluation, homozygosity for the Ser9Gly variant (allele 2) of the dopamine DRD3 gene and the genotype distribution are shown in Table 1 . In the total sample, the frequency DRD3 gene was more common among schizophrenic patients with longitudinal TD (TD-developed and TDwas 69% for allele 1 (wild-type) and 31% for allele 2 (Ser9Gly polymorphism). The frequency of the 1-1, 1-persistent) as compared to the TD-fluctuating and TDnever group (24% vs 6%; P = 0.066, odds ratio 4.95 2 and 2-2 genotype was 51%, 36% and 13%, respectively, indicating a higher than expected number of 2-(95% CI 0.92-32.92). Longitudinal TD was present in six out of nine subjects (67%) with the 2-2 genotype, 2 homozygotes and a lower than expected number of 1-2 heterozygotes, although the deviation from a Hardyin nine out of 32 heterozygotes (28%) and in 10 out of 34 patients (29%) with the 1-1 genotype. Weinberg equilibrium was non-significant ( 2 = 2.52, d.f. = 2, n.s.).
The apparent accumulation of subjects homozygous for the Ser9Gly allele among TD patients was further Correlation of the cross-sectional TD results and the genetic data demonstrated a significantly higher freindicated by the higher than expected number of the 2-2 genotype and lower than estimated number of hetquency of allele 2 among the patients with TD as compared to the subjects without this extrapyramidal sideerozygous subjects (Tables 1 and 2 ), although the departure from a Hardy-Weinberg equilibrium was effect (38% vs 23%; P = 0.035, odds ratio 2.02 (95% CI non-significant, both in the cross-sectional subgroup of zygosity for the DRD3 gene (1-1 or 2-2 genotype) among certain groups of schizophrenic subjects as compared TD patients ( 2 = 4.38, d.f. = 2; n.s.) and among the schizophrenic subjects with longitudinal TD ( 2 = 1.70, to healthy controls, 5-8,10-11 whereas other association and linkage studies have failed to detect any corred.f. = 2; n.s.).
lation between schizophrenia and the DRD3 gene polymorphism. [12] [13] [14] [15] [16] [17] [18] [19] [20] [58] [59] Recently, Shaikh and colleagues Discussion have performed a meta-analysis which shows evidence for a modest association between DRD3 homozygosity The main finding in this study is the high frequency of homozygosity for the Ser9Gly variant (allele 2) of the and schizophrenia. 9 The authors, however, raise the possibility that the results could be biased if the DRD3 gene among neuroleptic-treated schizophrenic patients with TD in both the cross-sectional and the patients were not genetically comparable to the controls. Our present data demonstrate a marked accumulongitudinal evaluation (22% and 24%, respectively), as compared with the relative under-representation of lation of schizophrenic patients homozygous for the polymorphic allele 2 (2-2 genotype), but not the 1-1 this genotype in patients with no or fluctuating TD (4-6%). Our present results therefore indicate that autosogenotype, in the TD group. In most of the studies indicating an association between schizophrenia and mal inheritance of two polymorphic Ser9Gly alleles is a susceptibility factor for the development of TD.
homozygosity at the DRD3 gene, a similar over-representation of the 2-2 genotype is apparently present in the patient group. 5-8,10-11 Such an over-representation DRD3 gene polymorphism and schizophrenia The dopamine D3 receptor is a member of the D2-like could be due to selective inclusion of subjects with TD from the total population of schizophrenic patients, subfamily of G protein-coupled receptors, which are all characterized by seven hydrophobic, membrane-spansince subjects suffering from this movement disorder may need more frequent psychiatric care compared ning regions. In the brain, DRD3 is scarcely expressed, with selective expression in certain limbic areas, with patients without extrapyramidal side-effects and could thereby have an increased chance of being especially the nucleus accumbens and the olfactory tubercle. [56] [57] The point mutation in the DRD3 gene, included in scientific projects. As a consequence, the frequency of homozygosity may be different between which leads to the predicted Ser9Gly variant in the Nterminal part of the receptor protein, was first the patient group and the controls, not because of the illness per se, but due to a selection bias involving a described by Lannfelt et al in 1992 . 39 Based on the dopamine hypothesis of schizophrenia, a large number putative association between a certain side-effect (TD) and a genetic marker (2-2 genotype). Our present samof studies have subsequently investigated the presence of this receptor gene polymorphism in schizophrenic ple (Table 1) included about 60% of the Nithsdale cohort of schizophrenic patients. The 100 subjects patients. In our sample of 100 schizophrenic subjects, the frequency of allele 2 and the homozygous 2-2 genoexamined were on average more severely ill than the rest of the patients and demonstrated a high prevalence type was 31% and 13% respectively. This is in accordance with previous studies which have reported that of TD as well as a tendency towards an over-representation of the 2-2 genotype. the frequency of allele 2 varies between 28-41%, with 5-22% of the subjects being 2-2 homozygotes in different samples of schizophrenic patients of Caucasian or DRD3 gene polymorphism and risk for TD Results from different pharmacological studies may Asian ethnicity.
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Several investigators have found an excess of homosupport the observed association between TD and homozygosity for the Ser9Gly variant (2-2 genotype) of in the nucleus accumbens and the olfactory tubercle, although expression is also detectable in other areas such the dopamine D3 receptor. The dopamine agonist 7-OH-DPAT, which preferentially binds to DRD3, seems as the substantia nigra, the caudate and the putamen.
56-57 Determination of changes in brain DRD3 mRNA levels to inhibit locomotor activity, [41] [42] [43] whereas a D3-preferring antagonist may cause hyperactivity. 44 The atypical following long-term neuroleptic exposure has yielded conflicting results. 69-72 Wang and colleagues recently neuroleptic clozapine, which only very seldom has been associated with cases of TD, has a low affinity reported that chronic exposure to dopamine receptor antagonists may up-regulate the expression of DRD3. 73 towards DRD3, in contrast to most other classical neuroleptics. 56, 60 An investigation of a dopamine D4 recepThe ability of the different anti-dopaminergic agents to induce the receptor mRNA level was apparently depentor variant in Africans has demonstrated that a valine to glycine substitution in the extracellular, liganddent on their affinity for the dopamine D3 receptor, and clozapine thus had no effect on D3 mRNA levels in any binding part of the protein makes the receptor two orders of magnitude less sensitive to dopamine. 61 In a brain region studied. 73 It is possible that DRD3 may function as an inhibitory autoreceptor, modulating the similar way, the Ser9Gly polymorphism could lead to an altered function of DRD3 receptor. Indeed, a recent activity of dopaminergic neurons. 56, 74 We therefore postulate that the Ser9Gly variant of DRD3 displays altered expression study has indicated that the Ser9Gly variant displays significantly higher binding affinity for dopabinding affinity or functional response to dopamine or neuroleptics. Thus, subjects homozygous for this variant mine, as compared to the wild-type dopamine D3 receptor, although the functional consequences of this (2-2 genotype), but not 1-2 heterozygotes or 1-1 homozygotes, could experience a disruption of a putative DRD3-difference, if any, remain to be established. 40 The putative role of the DRD3 gene polymorphism as mediated autoreceptor modulation of locomotor activity.
In conclusion, our data indicate that homozygosity a risk factor for TD has been further underscored by data obtained from mice lacking functional D3 receptors. 45 for the Ser9Gly polymorphism of the DRD3 gene is a risk factor for the development and persistence of TD Behavioral analysis of mutant mice demonstrated that the receptor defect was associated with increased locoin schizophrenia. This result may, if confirmed, improve the understanding of the pathophysiological motor activity and hyperactivity in an exploratory test. The mice had apparently no gross developmental defimechanisms of TD and may also be used to detect susceptible patients prior to treatment as well as influence cits. Since mice lacking dopamine D2 receptors display parkinsonian-like locomotor impairment, 62 the D2 and the design and choice of future anti-psychotic drugs.
The correlation between a serious motor side-effect D3 receptors may have opposing effects upon the regulation of locomotor activity.
(TD) and a genetic marker (2-2 genotype of DRD3) could lead to selection bias in the sampling of schizoAs this manuscript was in preparation, Gaitonde and co-workers reported that 'no significant association phrenic patients for genetic studies and may therefore explain the apparent association between schizowas found between genotype and movement disorder scores' in DRD3-genotyped schizophrenic patients. 20 phrenia per se and homozygosity for the DRD3 gene. The sample was predominantly drawn from a clozapine clinic, composed largely of patients who had not Acknowledgements responded to conventional neuroleptic drugs. Such clozapine-treated patients would be expected to have
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